Federal Register Notice: FDA has determined the regulatory review period for Astellas Pharma’s Vaprisol is 2,796 days for extending a patent that claims the human drug product. FDA recently approved for marketing Vaprisol for treating euvolemic hyponatremia in hospitalized patients. To view this notice, click here.
